Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)

Next Previous
Trial Profile

BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risankizumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms IMMvent
  • Sponsors AbbVie; Boehringer Ingelheim Pharma KG

    • Most Recent Events

    • 21 Mar 2023 Results of pooled analysis (n=1306 from four studies UltIMMa-1 and -2, IMMvent, and IMMhance) assessing racial and ethnic diversity for efficacy and safety outcomes presented at the American Academy of Dermatology annual Meeting 2023
    • 01 Nov 2022 Results of post hoc analysis of three studies(N = 53,IMMvent NCT02694523, N = 172, UltIMMa-1 NCT02684370and UltIMMa-2 NCT02684357) assessing Psoriasis Area Severity Index and Dermatology Life Quality Index results from patients who switched to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients published in the Journal of Dermatological Treatment
    • 25 Apr 2021 Results (n=2,109) of pooled analysis from three phase 3 trials ((NCT02684370, NCT02684357, NCT02694523) evaluating the impact of risankizumab withdrawal on HRQL measured by the Dermatology Life Quality Index (DLQI) presented at the American Academy of Dermatology Virtual Meeting Experience 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top